• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

GE Stock Jolted as Key Analyst Cuts Target Price

GE stock hasn't solved its free cash flow conundrum, and might not for some time, says a key analyst.
By KEVIN CURRAN Apr 08, 2019 | 08:39 AM EDT
Stocks quotes in this article: GE, RYCEY, HON, DHR

General Electric (GE)  stock is reversing its 2019 trajectory as a bellwether analyst has become a bear once again.

Shares of the Boston-based company fell over 5% in pre-market trading, taking some steam out of a comeback in stock price that has marked an over 30% run year to date, following the key report from JP Morgan analyst Stephen Tusa.

"We believe many investors are underestimating the severity of the challenges and underlying risks at GE, while overestimating the value of small positives," Tusa said in a note on Monday morning.

"The driver of the downgrade is our view that the Street is significantly over projecting the bounce in FCF in the coming years, off levels that we calculate at zero currently, as Power/Renewables remains weak, GECS will likely consume material cash for the foreseeable future, Aviation fundamentals, as per underlying FCF, are weaker than meet the eye, while lingering sector high leverage including entitlements leaves the company vulnerable to liquidity issues in the event of a recession, for which a potentially dilutive sale of the rest of Healthcare may be needed," he added.

He called out his fellow analysts, pondering the reason for so many to cut free cash flow estimates, but stubbornly maintain price targets.

"After implying 2019 should have minimal impact and cutting to -$1 billion on free cash flow, some Sell Side Bulls are now cutting '20 from what had been about $6 billion to now $3 billion (still too high, in our view) while maintaining numbers of >$7 B in '21, which we view as unrealistic," he concluded.

Tusa added that recently announced sale of the Biopharma business to Danaher (DHR) might not provide the relief that many investors expect.

As a result of the problematic outlook that is going unrecognized, he set a paltry $5 price target for the stock and downgraded to a "Sell" rating. His rating is now the lowest estimate among Wall Street analysts.

The move from Tusa is particularly pertinent to shareholders as he is an analyst with some of the best access to the company and has also acted as a bellwether for the share price.

On December 13, Tusa backed off of his "Sell" rating and upgraded to "Neutral", essentially marking the bottom for the stock late last year. Shares have run about 50% to the upside since this call.

STOP TRADING! Tusa Goes from Sell to Hold $GE...the bottom is being put in. Congratulations to one of the most amazing, incredible calls of a lifetime, to sell GE... Steve Tusa from JP Morgan. Research at its best. Maybe best ever..

— Jim Cramer (@jimcramer) December 13, 2018

CEO Larry Culp further encouraged investors by touting a turnaround by 2020 and positive free cash flow in the struggling power business by 2021.

"It's going to take some time, and we won't be finished come New Year's Eve, but if you give us a little bit of time we will, I think, make a lot of progress," Culp told Jim Cramer on Mad Money in mid-March.

Tusa now expects that the company may be over-promising again and might not actually have the time it needs to fix the key metric ahead of a potential recession by 2021.

He compared the situation the one seen by Rolls Royce (RYCEY) amid its 2013 to 2016 decline, eschewing comparisons to his top sector pick Honeywell (HON) and a more bearish comparison to the defunct Tyco Int'l.

"Looking at Rolls Royce shows how the standing stock price at GE gives more than enough credit for any snap back, in a situation with far less macro support and more challenged leverage, but one which we think is instructive nonetheless," Tusa explained.

He noted that the multiple for the company collapsed from around 40 times forward earnings to just 15 times as more visibility on its cash flow issues came more clearly into view. Tusa expects a similar trajectory could well come into play as more stock watchers recognize the remaining issues.

"Given a low quality of earnings, we believe free cash flow remains the most relevant metric for valuation, on which the stock screens as expensive," Tusa explained as motivating his reversion to a pessimistic outlook. "While these challenges are better understood and the debate has become more balanced, as opposed to being overlooked by most Bulls in the past, we see a real bear case in potential recession for a materially lower equity value than even our base cast price target implies, given high leverage, and mechanical math around entitlements. Given the significant move in the stock since December, the risk/reward has tilted back negative, and we are again Underweight."

Tusa is well known for his consistently correct calls to the downside as the company floundered under former CEOs Jeff Immelt and John Flannery. He held onto a "Sell" rating for the stock for over two years as shares lost three quarters of their value.

As such, investors would be wise to expect share erosion to come. History has a way of repeating itself.

(Danaher and Honeywell are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells DHR or HON? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: IPOs | Restructuring | Investing | Stocks | Bearish Bet | Energy | Life Sciences | Industrials | Analyst Actions | Stock of the Day

More from Stocks

Marveling at the Market's Move? It's All About Momentum

James "Rev Shark" DePorre
Jan 19, 2021 4:41 PM EST

No news can explain the action -- whether the bears believe it or not.

Surface Oncology Is Set for Further Gains - How to Buy It

Bruce Kamich
Jan 19, 2021 3:25 PM EST

Here's our price objective.

My Preference With OneSpan Is Calls So I Can Define My Risk

Timothy Collins
Jan 19, 2021 2:36 PM EST

The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.

A Top Biotechnology Play for 2021

James "Rev Shark" DePorre
Jan 19, 2021 2:07 PM EST

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

Boot Barn Gets a Quant Upgrade: Do the Charts Fit?

Bruce Kamich
Jan 19, 2021 1:53 PM EST

Here's our latest analysis and trading strategy for the shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login